Drug intelligence / Profile preview

NKX-070

Development stage: Discontinued
Lead developer: Nkarta
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NKX-070 is a **CAR-NK cell therapy** targeting **CD70** (CD70 antigen), developed as an immunotherapy agent for hematologic malignancies. The drug is classified as a CD70 inhibitor and was originally developed by Nkarta and CRISPR Therapeutics for the treatment of hematologic neoplasms. Its mechanism of action involves engineered natural killer cells that recognize and inhibit cells expressing CD70, a protein frequently upregulated in certain blood cancers, aiming to promote targeted cell death in malignant cells[1].

Brand names: NKX-070NKX070NKX 070
Other names: NKX-070NKX070NKX 070

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on NKX-070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKX-070.

Explore the full profile